112 related articles for article (PubMed ID: 6577835)
21. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
22. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
Carlson K; Hjorth M; Knudsen LM;
Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
[TBL] [Abstract][Full Text] [Related]
23. [Maintenance hemodialysis in IgD- lambda -type multiple myeloma associated with severe renal failure].
Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H
Nihon Jinzo Gakkai Shi; 1994 Feb; 36(2):177-81. PubMed ID: 8139151
[TBL] [Abstract][Full Text] [Related]
24. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
25. Should patients with renal failure associated with myeloma be dialysed?
Coward RA; Mallick NP; Delamore IW
Br Med J (Clin Res Ed); 1983 Nov; 287(6405):1575-8. PubMed ID: 6416509
[TBL] [Abstract][Full Text] [Related]
26. "Long-term" survival in light-chain myeloma with dialysis therapy alone.
Boyce NW; Holdsworth SR; Thomson NM; Atkins RC
Aust N Z J Med; 1984 Oct; 14(5):676-7. PubMed ID: 6442138
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
Lazarus HM; Adelstein DJ; Herzig RH; Smith MC
Am J Kidney Dis; 1983 Mar; 2(5):521-5. PubMed ID: 6402926
[TBL] [Abstract][Full Text] [Related]
28. [Successful haemodialysis treatment of acute renal failure in a patient with multiple myeloma (author's transl)].
Kopsa H; Schmidt P; Zazgornik J; Balcke P; Deutsch E
Med Klin; 1978 May; 73(18):668-70. PubMed ID: 651757
[TBL] [Abstract][Full Text] [Related]
29. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy.
Johnson WJ; Kyle RA; Pineda AA; O'Brien PC; Holley KE
Arch Intern Med; 1990 Apr; 150(4):863-9. PubMed ID: 2183734
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
31. [End-stage chronic renal failure in myeloma: results of dialysis].
Duvic C; Viron B; Michel C; Mignon F
Rev Med Interne; 1993; 14(8):792-8. PubMed ID: 8191093
[TBL] [Abstract][Full Text] [Related]
32. [New insights in the treatment of myeloma with renal failure].
Moumas E; Hanf W; Desport E; Abraham J; Delbès S; Debiais C; Lacotte-Thierry L; Touchard G; Jaccard A; Fermand JP; Bridoux F
Nephrol Ther; 2011 Nov; 7(6):457-66. PubMed ID: 21515102
[TBL] [Abstract][Full Text] [Related]
33. Managing the complications of plasma cell myeloma.
Cohen HJ; Rundles RW
Arch Intern Med; 1975 Jan; 135(1):177-84. PubMed ID: 122891
[TBL] [Abstract][Full Text] [Related]
34. Management and prognosis of multiple myeloma.
Kyle RA; Elveback LR
Mayo Clin Proc; 1976 Dec; 51(12):751-60. PubMed ID: 792581
[TBL] [Abstract][Full Text] [Related]
35. Treatment of acute renal failure due to myeloma kidney.
Bear RA; Cole EH; Lang A; Johnson M
Can Med Assoc J; 1980 Oct; 123(8):750-3. PubMed ID: 7004618
[TBL] [Abstract][Full Text] [Related]
36. [Multiple myeloma nephropathy as a cause of renal failure--diagnostic difficulties and prospects for treatment].
Polak G; Tomczak-Watras W; Nartowicz E
Pol Arch Med Wewn; 1998 Sep; 100(3):257-61. PubMed ID: 10335031
[TBL] [Abstract][Full Text] [Related]
37. Renal transplantation in multiple myeloma. A case report.
Humphrey RL; Wright JR; Zachary JB; Sterioff S; DeFronzo RA
Ann Intern Med; 1975 Nov; 83(5):651-3. PubMed ID: 1106279
[TBL] [Abstract][Full Text] [Related]
38. Severe renal failure in multiple myeloma.
Cosio FG; Pence TV; Shapiro FL; Kjellstrand CM
Clin Nephrol; 1981 Apr; 15(4):206-10. PubMed ID: 7237869
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
40. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
